Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra

World Health Organization Wants Prices Lowered

Executive Summary

The World Health Organization has taken the unusual step of calling for lower drug prices to help COVID-19 patients access IL-6 therapies in developing nations.

You may also be interested in...



Hetero To Debut Biosimilar Actemra, Giving India Grasp On Supplies Security

The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.

Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’

The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.

More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?

The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel